jan 1, 2013 - Ado-Trastuzumab Emtansine (T-DM1)
Description:
FDA approves ado-trastuzumab emtansine (T-DM1) for the treatment of patients with HER2-positive breast cancer who were previously treated with trastuzumab and/or a taxane drug. T-DM1 is an immunotoxin (an antibody-drug conjugate) that is made by chemically linking the monoclonal antibody trastuzumab to the cytotoxic agent mertansine, which inhibits cell proliferation by blocking the formation of microtubules.Added to timeline:
Date:
jan 1, 2013
Now
~ 13 years ago